Leadership Team

Forward with the weight of experience

Contact Us

Fortis Life Sciences is led by executives with deep industry expertise, strategic insight, and a steadfast commitment to innovation. With domain experience across antibodies, diagnostics, genomics, nanomaterials, and viral vectors, they bring a proven record of strengthening respected brands and driving growth.

Together, they guide the company forward with clarity, purpose, and a bold focus on sustainable progress that supports customer discoveries that shape medicine, diagnostics, and applied science.

See What’s New

Executive Team

John Bagnuolo

John Bagnuolo

Chief Executive Officer

John R. Bagnuolo is a seasoned CEO who has led multiple exits for private equity sponsored companies. He has extensive experience in the healthcare, technology and pharmaceutical industries. He held senior leadership positions with Danaher & Johnson & Johnson earlier in his career.

John’s focus is on building scalable & sustainable growth cultures. He is a hands-on leader who builds strong teams and leads through his team while building strong leaders at all levels of the organization.

Most recently he was the CEO of Transcendia Corporation, a provider of engineered materials serving pharmaceutical & healthcare customers.

John holds an M.B.A. from DePaul University’s Kellstadt Graduate School of Business and a B.S. in Mechanical Engineering Technology from Northern Illinois University.

John Hakola

John Hakola

Chief Financial Officer

John leads the overall finance, accounting, and IT teams at Fortis, bringing more than 20 years of experience to his role. He has led global finance teams and has a wide range of overall corporate governance experience. John has a passion for developing strong teams and driving engagement cross-functionally.

Prior to joining Fortis, John was the Vice President, Principal Accounting Officer at Orchid Orthopedic Solutions, a contract manufacturer in the orthopedic industry. During his 14 years at Orchid, John held several roles within the finance and accounting team, prior to becoming the Principal Accounting Officer. Prior to Orchid, John started his career in public accounting, spending 8 years with PwC, mainly serving Life Science companies.

John earned his Bachelor of Business Administration degree from Edinboro University of Pennsylvania and his MBA from Ohio University.

Scott A. Taillie

Scott A. Taillie

Chief Commercial Officer

Scott leads Commercial strategy and marketing for Fortis Life Sciences across the businesses. He brings more than 30 years of experience in life sciences commercial leadership, spanning diagnostics, toxicology, and laboratory services.

Prior to joining Fortis, Scott held senior leadership roles at Alere and Abbott. He serves as Vice Chairman of The National Drug and Alcohol Screening Association and a Trustee of the NDASA Foundation.

Scott holds a B.A. in Business Administration and Marketing from Webster University.

Cindy Horton

Cindy Horton

General Manager, Antibody Solutions

Cindy Horton is a seasoned biotech executive with more than 20 years of leadership experience in point-of-care diagnostics and laboratory services.

She spent nearly two decades at Alere, including as Vice President and General Manager of its Toxicology Core business, and later served as Senior Vice President of Abbott's Toxicology business unit. She went on to serve as CEO of Healgen Scientific and Premier Biotech.

Cindy's expertise spans commercial growth, operational excellence, strategic planning, and business process improvement.

Jeff Hurst

Jeff Hurst

Vice President, Commercial Operations

Jeff has over 15 years of experience bringing science-driven technologies to market across diagnostics, biopharma, and advanced optical technologies.

As Vice President, Commercial Operations, he draws on his experience in sales, marketing, product management, and operations to connect technical capabilities with customer needs.

Jeff has a B.S. in Chemistry from the University of Washington.

Chris Woodward

Chris Woodward

Senior Director, Antibody Solutions Business Unit, Sales and Marketing

Chris Woodward is a senior commercial leader with extensive experience driving revenue growth across life sciences and medical instrumentation sectors.

He has held leadership roles at Fortis Life Sciences, Cell Signaling Technology, Miltenyi Biotec, Thermo Fisher Scientific, and WCG Clinical.

Chris holds a B.B.A. in Marketing from Duquesne University.

Board of Directors

Strategic oversight and guidance that keep Fortis disciplined, growth-oriented, and aligned with long-term scientific and commercial objectives.

Darren M. Black

Darren M. Black

Board of Directors

Darren joined Summit Partners in 2013 and focuses on healthcare and life sciences investments. He currently serves on multiple healthcare boards including LifeStance Health, Sound Physicians, U.S. Renal Care, VaxCare, and others.

Prior to Summit, Darren was a Managing Partner at SV Life Sciences and previously co-founded and led two healthcare companies. He began his career in healthcare consulting at Accenture.

Darren holds an A.B. from Harvard College and an MBA from the Wharton School of the University of Pennsylvania.

Ross D. Stern

Ross D. Stern

Board of Directors

Ross joined Summit Partners in 2009 and focuses on healthcare and life sciences investments. His board experience spans healthcare services, practice management, diagnostics, and specialty pharmaceutical platforms.

Previously, Ross worked at the Center for Medicare and Medicaid Innovation and in healthcare investment banking at Cowen & Company.

Ross holds a B.A. from Bowdoin College and an MBA from the Wharton School of the University of Pennsylvania.

Julie Coletti

Julie Coletti

Board of Directors

Julie Coletti is EVP, Chief Legal & Regulatory Officer at Align Technology, a global medical device company and leader in digital dentistry. She advises the Board and Executive Committee and leads legal, regulatory, and quality organizations worldwide.

Prior to Align, Julie served as Vice President and Global General Counsel for Danaher's Dental Platform and held senior leadership roles at Bayer HealthCare.

Heiner Dreismann, PhD

Heiner Dreismann, PhD

Board of Directors

Heiner brings more than 35 years of experience in molecular diagnostics and life sciences leadership. A pioneer in the early commercialization of PCR technology, he held multiple global leadership roles at Roche Diagnostics, including President and CEO of Roche Molecular Systems.

Heiner has served on numerous public and private boards across the U.S., Europe, and Israel and is widely recognized for advancing molecular diagnostic platforms globally.

Explore More